Skip to main content
Publication of the activity report and financial information for the first half-year (April – Sept. 2019)
December 3, 2019
The MedinCell General Meeting votes to include the “Raison d’être” of the Company in its articles of association
September 10, 2019
MedinCell receives a new grant to develop a best-in-class long-acting injectable product for HIV PrEP
September 4, 2019
MedinCell partners to address the untapped financial potential in Animal Health
August 28, 2019
Long-acting injectable antipsychotic using MedinCell’s technology receives FDA IND clearance to initiate clinical activities
August 26, 2019
Publication of the 2018/2019 Annual Financial Report
July 31, 2019
Third long-acting injectable antipsychotic using MedinCell’s technology enters preclinical development
July 9, 2019
MedinCell receives 7,5 M€ from the European Bank of Investment (EIB)
July 7, 2019
MedinCell announces 2018/19 fiscal year results
June 4, 2019
Shareholders audioconference and publication of the results for the 2018-2019 financial year, on June 4, 2019
May 22, 2019
